Multi-Site

Multi-Site

9671: Exceptional Responders Pilot Study: Molecular Profiling of tumors from cancer patients who are Exceptional Responders

9846: Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program

EAQ152: A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling

EAY131 (MATCH): Molecular Analysis for Therapy Choice

Kyowa 0761-014: Open-label, Multicenter Phase I/II Study of Mogamulizumab in Combination with Nivolumab in Subjects with Locally Advanced or Metastatic Solid Tumors (Presently in Phase II)

S1415CD: A Pragmatic Trial to Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia – Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)

S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (For patients that did not have a match to a molecularly guided therapy on EAY131 – MATCH or who progressed on molecularly-matched therapy and have no further molecularly-matched treatment recommendations)

TAPUR: The Targeted Agent and Profiling Utilization Registry Study

By | 2017-09-08T13:28:57+00:00 September 8th, 2017|Categories: WMCC Clinical Trials|Comments Off on Multi-Site

About the Author: